Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
patients preferred a face-to-face consultation, 39% said that they would like to use a
TC again. Cancer patients were a bit more worried about getting infected with SARS-
Coronavirus (22%) compared to the 900 norm participants (17%). Remarkably, norm par-
ticipants had worse QoL scores than measured before the crisis, and we did not see
clinically relevant differences with the QoL scores of cancer patients in the current
comparison. Norm participants more often reported depression (13% vs. 10%) and
loneliness (11% vs. 7%) than cancer patients (p < 0.05).

Conclusions: Up to one in four cancer patients reported changes in cancer care in the
first weeks of the COVID-19 crisis, associated with vulnerability factors. Follow-up will
show its impact on outcomes. The crisis seems to have more impact on QoL and
mental wellbeing in the norm population than in cancer patients.

Legal entity responsible for the study: The authors.

Funding: Dutch Research Council.

Disclosure: G. Vink: Research grant/funding (institution), Travel/ Accommodation/ Expenses: Serv-
er; Research grant/Funding (installation). Bayer: Research grant/Funding (institution): Merck: M.
Koopman: Honoraria (institution). Research grant/funding (installation): BMS, Nordic Pharma;
Servier: Honoraria (institution): Amgen; Research grant/Funding (installation): Bayer; Merck-Serono;
Roche; Sandoz-Aventis; NVMD. H.W.M. van Laarhoven: Research grant/Funding (installation): Bayer;
Advisory/Consultancy; Research grant/funding (installation): BMS: Nordic Pharma; Servier;
Research grant/funding (installation): Celgene; Janssen; Lilly; Philips; Roche; Advisory/Consultancy:
MSD, Novartis. All other authors have declared no conflicts of interest.

https://doi.org/10.1016/j.annonc.2020.08.1750

1688P Outcome of older cancer patients infected with COVID-19 at Gustave Roussy Cancer Center

M. Hauchecorne1, C. Baldini1, S. Foulon2, A. Bayle1, B. Gachat1, F. Pommeret3, C. Wilkeens4, F. Griselli5, F. Netzer6, C. Balleyguier7, S. Ammari8, F. André9, C. Scotté10, B. Besse11, I-C. Soria12, F. Barlesi13, L. Albige14

1Oncogenicity, Gustave Roussy - Cancer Campus, Villejuif, France; 2Dép of Drug Development Department, Gustave Roussy, Villejuif, France; 3Biostatistics, Gustave Roussy - Cancer Campus, Villejuif, France; 4Supportive care, Gustave Roussy - Cancer Campus, Villejuif, France; 5Supportive care, Gustave Roussy - Cancer Campus, Villejuif, France; 6Hematology Department, Gustave Roussy - Cancer Campus, Villejuif, France; 7Microbiology, Gustave Roussy - Cancer Campus, Villejuif, France; 8Pharmacy Development Department, Institut Gustave Roussy, Villejuif, France; 9Radiology Department, Gus-
< | >